• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Epix and Mallinckrodt expand R&D deal

Article

Contrast agent firms Epix Medical of Cambridge, MA, and Mallinckrodt of St. Louis announced this month an expansion of their existing agreement to research and develop MR imaging technologies. Epix and Mallinckrodt will both fund research in

Contrast agent firms Epix Medical of Cambridge, MA, and Mallinckrodt of St. Louis announced this month an expansion of their existing agreement to research and develop MR imaging technologies. Epix and Mallinckrodt will both fund research in intravascular MRI contrast agents, and they will pursue additional applications for AngioMark, Epix’s imaging agent, such as identifying peripheral vascular disease, coronary artery disease, and breast cancer. AngioMark has completed phase II clinical trials for peripheral vascular use, and is in phase II trials for the other two indications. Epix and Mallinckrodt would also like to research the use of AngioMark for macro- and micro-vessel imaging.

Recent Videos
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Related Content
© 2025 MJH Life Sciences

All rights reserved.